These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 27324802

  • 1. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
    Heinz WJ, Buchheidt D, Ullmann AJ.
    Mycoses; 2016 Aug; 59(8):480-93. PubMed ID: 27324802
    [Abstract] [Full Text] [Related]

  • 2. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G, Figgitt D.
    Drugs; 2003 Aug; 63(20):2235-63. PubMed ID: 14498760
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA, Chodakewitz JA, Severino ME, Saddier P, Berman RS, Ryan DM, Dinubile MJ, Patterson TF, Denning DW, Walsh TJ.
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [Abstract] [Full Text] [Related]

  • 4. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL.
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [Abstract] [Full Text] [Related]

  • 5. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
    Groetzner J, Kaczmarek I, Wittwer T, Strauch J, Meiser B, Wahlers T, Daebritz S, Reichart B.
    J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R.
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
    León-Gil C, Ubeda-Iglesias A, Loza-Vázquez A, de la Torre MV, Raurich-Puigdevall JM, Alvarez-Sánchez B, Ortiz-Leyva C, Domínguez-Roldán JM, Socías-Crespi L, Garnacho-Montero J, ProCAS Study Group.
    Rev Esp Quimioter; 2012 Dec; 25(4):274-82. PubMed ID: 23303260
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY.
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [Abstract] [Full Text] [Related]

  • 14. Caspofungin: first approved agent in a new class of antifungals.
    Johnson MD, Perfect JR.
    Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003
    [Abstract] [Full Text] [Related]

  • 15. Caspofungin therapy in immunocompromised children and neonates.
    Somer A, Törün SH, Salman N.
    Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
    Maertens J, Egerer G, Shin WS, Reichert D, Stek M, Chandwani S, Shivaprakash M, Viscoli C, Study Team CAN-DOIA.
    BMC Infect Dis; 2010 Jun 22; 10():182. PubMed ID: 20569436
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage Aspergillosis Study Group.
    Clin Infect Dis; 2004 Dec 01; 39(11):1563-71. PubMed ID: 15578352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.